ABSTRACT
PURPOSE OF REVIEW: This review addresses treatment options for moderate to severe tricuspid valve regurgitation and the importance of right ventricular function and the pulmonary circulation. RECENT FINDINGS: Several interventional treatment options for severe tricuspid regurgitation have been developed including transcatheter edge-to-edge repair, annuloplasty and valve replacement. So far, transcatheter edge-to-edge repair is most frequently used with procedural success rates of more than 95% and improvements in functional and quality of life parameters for up to 2âyears. Right ventricular function as well as pulmonary artery pressure and resistance levels are important outcome predictors. Mean pulmonary artery pressure more than 30âmmHg, transpulmonary gradient more than 17âmmHg and right ventricular to pulmonary artery coupling ratio less than 0.406 indicate poor outcome. SUMMARY: Despite the remarkable safety of interventional treatment of severe tricuspid regurgitation right ventricular dysfunction and abnormal pulmonary hemodynamics are important determinants of procedural success and clinical outcome.Complete hemodynamic work-up should be an integral part of prerepair assessment although validated data predicting outcome are limited.
Subject(s)
Heart Valve Prosthesis Implantation , Pulmonary Circulation , Tricuspid Valve Insufficiency , Tricuspid Valve , Humans , Tricuspid Valve Insufficiency/surgery , Tricuspid Valve Insufficiency/physiopathology , Pulmonary Circulation/physiology , Tricuspid Valve/surgery , Tricuspid Valve/physiopathology , Heart Valve Prosthesis Implantation/methods , Cardiac Valve Annuloplasty/methods , Ventricular Dysfunction, Right/physiopathology , Hemodynamics/physiology , Ventricular Function, Right/physiology , Treatment Outcome , Cardiac Catheterization/methods , Quality of LifeSubject(s)
Aortic Valve , Cardiac Catheterization , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Humans , Treatment Outcome , Aortic Valve/surgery , Aortic Valve/diagnostic imaging , Aortic Valve/physiopathology , Cardiac Catheterization/instrumentation , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis Implantation/adverse effects , Suction , Transcatheter Aortic Valve Replacement/instrumentation , Transcatheter Aortic Valve Replacement/adverse effects , Male , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/surgery , Aortic Valve Stenosis/physiopathology , Aged, 80 and over , Echocardiography, Transesophageal , Prosthesis-Related Infections/surgery , Prosthesis-Related Infections/diagnostic imaging , Prosthesis-Related Infections/microbiology , Female , AgedSubject(s)
Aortic Valve Stenosis , Aortic Valve , Heart Valve Prosthesis Implantation , Humans , Aortic Valve/surgery , Aortic Valve Stenosis/surgery , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation/adverse effects , Transcatheter Aortic Valve Replacement/adverse effects , Randomized Controlled Trials as TopicABSTRACT
BACKGROUND: There is lack of evidence regarding safety, effectiveness and applicability of prehabilitation on cardiac surgery population, particularly in patients candidates to cardiac valve replacement. The aim of the study is to assess and compare the effect of a multimodal prehabilitation program on functional capacity in patients with severe aortic stenosis (AoS) and severe mitral regurgitation (MR) proposed for valve replacement surgery. METHODS: Secondary analysis from a randomised controlled trial whose main objective was to analyze the efficacy of a 4-6 weeks multimodal prehabilitation program in cardiac surgery on reducing postoperative complications. For this secondary analysis, only candidates for valve replacement surgery were selected. The primary outcome was the change in endurance time (ET) from baseline to preoperative assessment measured by a cycling constant work-rate cardiopulmonary exercise test. RESULTS: 68 patients were included in this secondary analysis, 34 (20 AoS and 14 MR) were allocated to the prehabilitation group and 34 (20 AoS and 14 MR) to control group. At baseline, patients with AoS had better left systolic ventricular function and lower prevalence of atrial fibrillation compared to MR (p = 0.022 and p = 0.035 respectively). After prehabilitation program, patients with MR showed greater improvement in ET than AoS patients (101% vs. 66% increase from baseline). No adverse events related to the prehabilitation program were observed. CONCLUSIONS: A 4-6 week exercise training program is safe and overall improves functional capacity in patients with severe AoS and MR. However, exercise response is different according to the cardiac valve type disfunction, and further studies are needed to know the factors that predispose some patients to have better training response. TRIAL REGISTRATION: The study has been registered on the Registry of National Institutes of Health ClinicalTrials.gov (NCT03466606) (05/03/2018).
Subject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis Implantation , Mitral Valve Insufficiency , Preoperative Exercise , Humans , Male , Female , Heart Valve Prosthesis Implantation/methods , Mitral Valve Insufficiency/surgery , Aortic Valve Stenosis/surgery , Aged , Middle Aged , Postoperative Complications/prevention & control , Postoperative Complications/epidemiology , Exercise Test/methods , Preoperative Care/methodsABSTRACT
Heart valve disease patients undergo multiple surgeries to replace structurally degraded valve prostheses, highlighting the need for valve replacements with growth and self-repair capacity. Given allogeneic valve transplantation's promise in meeting these goals by delivering a living valve replacement, we propose a framework for preserving and rehabilitating living valves ex vivo.
Subject(s)
Heart Defects, Congenital , Heart Valve Prosthesis , Humans , Heart Defects, Congenital/surgery , Heart Defects, Congenital/rehabilitation , Heart Valve Diseases/surgery , Heart Valve Diseases/rehabilitation , Heart Valves/surgery , Heart Valve Prosthesis Implantation/methodsABSTRACT
Infective endocarditis, particularly after implanting valve prostheses, poses significant surgical challenges, often requiring complex interventions. We describe a case of a 37-year-old male with Staphylococcus aureus endocarditis, unsuccessfully treated with mechanical valve prostheses. Continued infection led to the destruction of the intervalvular fibrous body, necessitating a Commando procedure involving radical debridement and replacement of both aortic and mitral valves with complex patch reconstruction. Prosthesis selection remains contentious, considering recurrence risk and long-term prognosis. Our case underscores timely intervention and meticulous technique in managing such complex situations. It highlights successful strategies for treating infective endocarditis with destruction of aortomitral continuity, emphasizing the pivotal role of the Commando procedure.
Subject(s)
Aortic Valve , Endocarditis, Bacterial , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Prosthesis-Related Infections , Staphylococcal Infections , Humans , Male , Adult , Endocarditis, Bacterial/surgery , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/etiology , Heart Valve Prosthesis/adverse effects , Staphylococcal Infections/diagnosis , Staphylococcal Infections/surgery , Staphylococcal Infections/etiology , Prosthesis-Related Infections/surgery , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/etiology , Aortic Valve/surgery , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis Implantation/adverse effects , Mitral Valve/surgery , Staphylococcus aureus/isolation & purification , Reoperation , Debridement/methodsABSTRACT
Left ventricular outflow tract obstruction is a rare complication following transcatheter mitral valve implantation. Diagnosing the underlying cause is mandatory to select from different treatment options. We report a case of stent-graft implantation into the left ventricular outflow tract for dynamic left ventricular outflow tract obstruction caused by systolic anterior motion of the anterior mitral valve leaflet (SAM).
Subject(s)
Heart Valve Prosthesis Implantation , Mitral Valve , Stents , Ventricular Outflow Obstruction , Humans , Ventricular Outflow Obstruction/surgery , Ventricular Outflow Obstruction/etiology , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/methods , Stents/adverse effects , Mitral Valve/surgery , Cardiac Catheterization/methods , Cardiac Catheterization/adverse effects , Mitral Valve Insufficiency/surgery , Male , Female , Aged , Ventricular Outflow Obstruction, LeftABSTRACT
INTRODUCTION: Avoiding patient-prosthesis mismatch (PPM) in patients with small aortic annulus (SAA) during aortic valve replacement (AVR) is still a challenging surgical problem. Among surgical options available, aortic root enlargement (ARE) and stentless valve implantation (SVI) are the two most commonly used strategies. This systematic review will be conducted searching for superiority evidence based on comparative studies between these two options. METHODS AND ANALYSIS: This systematic review will include all relevant articles published from 1 January 1946 to 31 March 2024, with available full texts from Medline (Ovid), Embase, Cochrane Library and Web of Science databases, without any language restriction. Observational studies and randomised controlled trials comparing surgical results of ARE versus SVI for AVR in patients with small aortic root will be screened. Studies will be classified into three groups: group 1 for studies that reported SVI or other tissue valve outcomes without comparing them with ARE outcomes; group 2 for studies that reported ARE outcomes without comparing them with SVI outcomes; and group 3 for studies that compared ARE outcomes with SVI outcomes. The quality of the evidence of each study will be evaluated according to Oxford Centre for Evidence-Based Medicine criteria. ETHICS AND DISSEMINATION: Ethical approval is not required because no primary data are collected. The findings will be presented at scientific conferences and/or reported in a peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: PROSPERO, CRD42023383793.
Subject(s)
Aortic Valve , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Systematic Reviews as Topic , Humans , Heart Valve Prosthesis Implantation/methods , Aortic Valve/surgery , Research Design , Aortic Valve Stenosis/surgery , Prosthesis DesignABSTRACT
OBJECTIVES: This study aimed to analyse the impact of preoperative septic cerebral embolism on early and late postoperative outcomes in patients with infective endocarditis undergoing valve surgery. METHODS: Retrospective multicentric study based on the Clinical Multicentric Project for Analysis of Infective Endocarditis in Germany (CAMPAIGN) registry comprising patients with infective endocarditis who underwent valve surgery between 1994 and 2018 at 6 German centres. Patients were divided into 2 groups for statistical comparison according to the presence or absence of preoperative septic cerebral embolism. Propensity score matching was performed for adjusted comparisons of postoperative outcomes. Primary outcomes were 30-day mortality and estimated 5-year survival. RESULTS: A total of 4917 patients were included in the analysis, 3909 (79.5%) patients without and 1008 (20.5%) patients with preoperative septic cerebral embolism. Patients with preoperative septic cerebral embolism had more baseline comorbidities. Mitral valve endocarditis (44.1% vs 33.0% P < 0.001), large vegetations >10 mm (43.1% vs 30.0%, P < 0.001), and Staphylococcus species infection (42.3% vs 21.3%, P < 0.001) were more frequent in the cerebral embolism group. Among patients with preoperative cerebral embolism, 286 (28.4%) patients had no stroke signs (silent stroke). After matching (1008 matched pairs), there was no statistically significant difference in 30-day mortality (20.1% vs 22.8%; P = 0.14) and 5-year survival (47.8% vs 49.1%; stratified log-rank P = 0.77) in patients with and without preoperative cerebral embolism, respectively. CONCLUSIONS: Preoperative septic cerebral embolism in patients with infective endocarditis requiring valve surgery does not negatively affect early or late mortality; therefore, it should not play a major role in deciding if surgery is to be performed.
Subject(s)
Intracranial Embolism , Humans , Male , Female , Retrospective Studies , Middle Aged , Intracranial Embolism/mortality , Intracranial Embolism/epidemiology , Aged , Endocarditis/surgery , Endocarditis/mortality , Endocarditis/complications , Germany/epidemiology , Postoperative Complications/epidemiology , Treatment Outcome , Registries , Endocarditis, Bacterial/surgery , Endocarditis, Bacterial/mortality , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/epidemiology , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/mortality , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/mortality , Heart Valve Prosthesis Implantation/statistics & numerical data , Heart Valves/surgery , Risk FactorsABSTRACT
OBJECTIVES: Both aortic root remodelling and aortic valve (AV) reimplantation have been used for valve-sparing root replacement in patients with aortic root aneurysm with or without aortic regurgitation. There is no clear evidence to support one technique over the another. This study aimed to compare remodelling with basal ring annuloplasty versus reimplantation on a multicentre level with the use of propensity-score matching. METHODS: This was a retrospective international multicentre study of patients undergoing remodelling or reimplantation between 2010 and 2021. Twenty-three preoperative covariates (including root dimensions and valve characteristics) were used for propensity-score matching. Perioperative outcomes were analysed along with longer-term freedom from AV reoperation/reintervention and other major valve-related events. RESULTS: Throughout the study period, 297 patients underwent remodelling and 281 had reimplantation. Using propensity-score matching, 112 pairs were selected and further compared. We did not find a statistically significant difference in perioperative outcomes between the matched groups. Patients after remodelling had significantly higher reintervention risk than after reimplantation over the median follow-up of 6 years (P = 0.016). The remodelling technique (P = 0.02), need for decalcification (P = 0.03) and degree of immediate postoperative AV regurgitation (P < 0.001) were defined as independent risk factors for later AV reintervention. After exclusion of patients with worse than mild AV regurgitation immediately after repair, both techniques functioned comparably (P = 0.089). CONCLUSIONS: AV reimplantation was associated with better valve function in longer-term postoperatively than remodelling. If optimal immediate repair outcome was achieved, both techniques provided comparable AV function.
Subject(s)
Aortic Valve Insufficiency , Aortic Valve , Propensity Score , Replantation , Humans , Male , Retrospective Studies , Female , Aortic Valve/surgery , Middle Aged , Replantation/methods , Aortic Valve Insufficiency/surgery , Aged , Reoperation/statistics & numerical data , Treatment Outcome , Heart Valve Prosthesis Implantation/methods , Cardiac Valve Annuloplasty/methods , AdultABSTRACT
Whipple disease is a rare systemic illness associated with weight loss, diarrhea, and arthralgia. Asymptomatic carriage is common, but the disease can be complicated by cardiac involvement and may result in culture-negative endocarditis. Cardiac manifestations of the disease can lead to death. This report presents the case of a 66-year-old man with Whipple disease and biventricular heart failure with cardiogenic shock. Medical therapy followed by successful replacement of the aortic and mitral valves resulted in substantial improvement.
Subject(s)
Endocarditis, Bacterial , Heart Failure , Heart Valve Prosthesis Implantation , Tropheryma , Whipple Disease , Humans , Male , Aged , Whipple Disease/diagnosis , Whipple Disease/complications , Whipple Disease/drug therapy , Whipple Disease/microbiology , Heart Failure/diagnosis , Heart Failure/microbiology , Heart Failure/therapy , Heart Failure/etiology , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/therapy , Tropheryma/isolation & purification , Treatment Outcome , Anti-Bacterial Agents/therapeutic use , Mitral Valve/diagnostic imaging , Mitral Valve/microbiology , Mitral Valve/surgery , Shock, Cardiogenic/etiology , Shock, Cardiogenic/therapy , Shock, Cardiogenic/diagnosis , Shock, Cardiogenic/microbiology , Aortic Valve/microbiology , Aortic Valve/surgery , Aortic Valve/diagnostic imaging , Heart Valve Diseases/microbiology , Heart Valve Diseases/diagnosis , Heart Valve Diseases/complicationsABSTRACT
BACKGROUND: Impaired hospitalizations for heart failure (HHF) and mortality are associated with tricuspid regurgitation (TR). OBJECTIVES: The objective of this study was to investigate the benefit of transcatheter tricuspid valve replacement (TTVR) over guideline-directed medical therapy (GDMT) in patients with symptomatic severe TR. METHODS: Between May 2020 and April 2023, 88 patients with symptomatic severe TR were treated in our center. Of these, 57 patients received GDMT alone, and 31 patients underwent combined TTVR and GDMT. We collected and analyzed baseline data, and follow-up information for both groups. The primary endpoints were all-cause mortality and the combined endpoint (including all-cause mortality and HHF). RESULTS: At a median follow-up of 20 (IQR 10-29) months, significant improvements were shown in TR severity, right ventricular function, and dimensions in TTVR group (all P < 0.001). It also resulted in superior survival rates (75.8% vs. 48.4%, P = 0.019), improved freedom from combined endpoint (61.5% vs. 45.9%, P = 0.007) and fewer major adverse events. After stratification by TRI-SCORE, the subgroup with < 6 points in the TTVR group exhibited a significant difference in the combined endpoint compared to the other subgroups (all P < 0.05), while no significant differences were observed in the GDMT subgroups (P = 0.680). CONCLUSIONS: The utilization of LuX-Valve in TTVR effectively improves TR and is associated with lower rates of major adverse events, HHF and all-cause mortality. The TRI-SCORE may help identify higher-benefit patients with TR from TTVR. Clinical trial registration ClinicalTrials.gov Protocol Registration System (NCT02917980).
Subject(s)
Heart Valve Prosthesis Implantation , Tricuspid Valve Insufficiency , Humans , Tricuspid Valve Insufficiency/surgery , Male , Female , Retrospective Studies , Aged , Heart Valve Prosthesis Implantation/methods , Tricuspid Valve/surgery , Middle Aged , Treatment Outcome , Severity of Illness Index , Cardiac Catheterization/methodsSubject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis Implantation , Transcatheter Aortic Valve Replacement , Humans , Transcatheter Aortic Valve Replacement/methods , Heart Valve Prosthesis Implantation/methods , Aortic Valve Stenosis/surgery , Treatment Outcome , Aortic Valve/surgery , Heart Valve ProsthesisABSTRACT
BACKGROUND: The Alterra adaptive prestent is a novel self-expanding device designed to provide a landing zone for the 29 mm SAPIEN 3 valve to treat pulmonary regurgitation in patients with a right ventricular outflow tract that is too large for a balloon expandable valve alone. The mechanism of fixation for the Alterra prestent is radial force from the self-expanding stent frame, combined with a unique set of flared "tines" that protrude from both ends of the stent. AIMS, METHODS, AND RESULTS: In this report, we describe 6 patients who underwent uncomplicated transcatheter pulmonary valve replacement with an Alterra adaptive prestent and SAPIEN 3 valve and had surveillance chest computed tomography (CT) scans performed 1 day to 21 months after implant. In each patient, the CT scan demonstrated extravascular extension of a portion of the Alterra prestent, without clinical sequelae, but with extension into the ascending aorta in 1 patient and contact with the ascending aorta, left pulmonary vein, or left atrial appendage in 3 others. CONCLUSIONS: Surveillance CT imaging shows that the Alterra prestent can perforate the pulmonary artery and/or right ventricle. Although no sequelae were seen in these patients, prestent perforation has the potential to be clinically important. Implanters should be aware of this finding and its potential implications. As experience with the Alterra prestent grows, it will be important to further define the risk factors, incidence, and implications of this phenomenon.
Subject(s)
Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Predictive Value of Tests , Prosthesis Design , Humans , Male , Female , Treatment Outcome , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis Implantation/adverse effects , Time Factors , Adult , Cardiac Catheterization/instrumentation , Cardiac Catheterization/adverse effects , Pulmonary Valve/diagnostic imaging , Pulmonary Valve/surgery , Pulmonary Valve/physiopathology , Pulmonary Valve Insufficiency/diagnostic imaging , Pulmonary Valve Insufficiency/physiopathology , Pulmonary Valve Insufficiency/surgery , Pulmonary Valve Insufficiency/etiology , Young Adult , Computed Tomography Angiography , Adolescent , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/physiopathology , Tomography, X-Ray ComputedABSTRACT
Tricuspid insufficiency has long been considered an entity with low prognostic importance and associated with symptoms and signs only secondarily to left heart pathology. Scientific research in recent years has debunked this myth, demonstrating a key role in determining symptoms and signs of right heart failure, even in advanced stages. In parallel, advances in transcatheter technologies have opened up treatment options even for patients with increased surgical risk, who were previously excluded from traditional surgical options, with increasingly convincing results in reducing symptoms and improving the quality of life of our patients. The contemporary challenge is to translate these messages into everyday clinical practice and to encourage the centralization of patients in centers that currently have the expertise for feasibility evaluation and subsequent treatment. In this Review, we will analyze the most recent evidence on the pathophysiology and diagnosis of tricuspid insufficiency, the latest recommendations from European guidelines, and we will try to illustrate the most common technologies for percutaneous treatment and the abundant evidence supporting them.